GLP-1 family
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Ji L, Jiang H, Bi Y, et al. · Nat Commun · 2023
PMID: 38092790 · DOI: 10.1038/s41467-023-44067-4
Summary
Phase 2 randomized, double-blind, placebo-controlled trial of once-weekly mazdutide (GLP-1/glucagon dual agonist) at 3, 4.5, 6 mg vs placebo over 24 weeks in 248 Chinese adults with overweight/obesity. Primary endpoint: percent change in body weight.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021